BY Richard Summerfield
Generic drug manufacturer Lannett Company has filed for a prepackaged Chapter 11 bankruptcy in the US Bankruptcy Court for the District of Delaware.
On 1 May, the company announced it had agreed to a restructuring support agreement (RSA) with holders of more than 80 percent of its 7.750 percent senior secured notes and 100 percent of the lenders party to the company’s second lien credit and guaranty agreement. The RSA will see the company seeking to significantly improve its financial position by eliminating approximately $597m of funded debt, including $511m of secured debt, through conversion of the secured debt into equity in the newly reorganised company.
Lannett, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.
“The significant support of our debtholders and other stakeholders demonstrates their confidence in the Company’s business plan and Lannett’s long-term strategy,” said Tim Crew, chief executive of Lannett. “Commencing our Chapter 11 cases is an important step toward strengthening our financial position, and we intend to move through this process quickly and without disruption for our customers and partners. We believe that implementing these transactions will enable us to continue manufacturing and producing safe, life-enhancing, and affordable generic pharmaceutical medicines.”
The company expects to continue to operate throughout the Chapter 11 process. The RSA and the prepackaged plan provide for vendors, employees and other partners to be paid in the ordinary course of business for obligations incurred prior to and after the commencement of the Chapter 11 cases. Lannett said it had sufficient liquidity to operate its businesses, including the payment of all such obligations. It expects to move through the process seamlessly, emerging as a stronger company better able to build for the future.
In April, Lannett was removed from the New York Stock Exchange (NYSE) after it fell below the continued listing standard requiring listed companies to maintain an average global market capitalisation of at least $15m over a consecutive 30-trading day period.
In December 2022, Lannett announced plans to close two research and development centres in Philadelphia, as well as eliminate 64 jobs, about 11 percent of its workforce. In a filing to the Pennsylvania Department of Labor and Industry, the company said these decisions were made in order “to streamline and realign our operations to ensure the continued progression of our existing pipeline and future growth”. The company said the facilities would be closed by 30 June 2023.
News: Generic Drugmaker Lannett Files for Chapter 11 Bankruptcy